Drug Maker Sanofi-Aventis to approve of Genzyme designed for $20B
Genzymes drugs in support of rare genetic disorders are happening a searing niche in support of life-size pharmaceutical companies wearisome to spread outside blockbuster pills to search out slammed by cheaper generic rivals bearing in mind a decade before so. Genzyme won U.S. agreement end could in favor of a newborn drug in favor of Pompe disease, an often fatal disorder featuring in which limb and respiratory muscles steadily weaken. Its experimental drug meant for multiple sclerosis is getting an expedited U.S.